Romosozumab Improves Lumbar Spine Bone Mass and Bone Strength Parameters Relative to Alendronate in Postmenopausal Women: Results From the ARCH Trial

In conclusion, romosozumab significantly improved bone mass and bone strength parameters at the lumbar spine compared with alendronate. These results are consistent with greater vertebral fracture risk reduction observed with romosozumab versus alendronate in ARCH and provide insights into structural determinants of this differential treatment effect.This article is protected by copyright. All rights reserved.

Source: Journal of Bone and Mineral Research - June 30, 2021 Category: Orthopaedics Authors: Jacques P. Brown, Klaus Engelke, Tony M. Keaveny, Arkadi Chines, Roland Chapurlat, A. Joseph Foldes, Xavier Nogues, Roberto Civitelli, Tobias De Villiers, Fabio Massari, Cristiano A. F. Zerbini, Zhenxun Wang, Mary K. Oates, Christopher Reckno Tags: Original Article Source Type: research